DPP-4 inhibitor hypoglycemic drugs can not only reduce the blood sugar concentration of patients, but also promote insulin secretion, and even repair damaged islet cells. Compared with traditional hypoglycemic drugs, they have many advantages such as high efficacy and low side effects.
The global DPP-4 Inhibitor Hypoglycemic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for DPP-4 Inhibitor Hypoglycemic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DPP-4 Inhibitor Hypoglycemic Drugs.
Report Scope
The DPP-4 Inhibitor Hypoglycemic Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global DPP-4 Inhibitor Hypoglycemic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the DPP-4 Inhibitor Hypoglycemic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Merck
MSD Pharma
Novartis
AstraZeneca Pharmaceuticals
Takeda Pharmaceutical
Boehringer Ingelheim International
Huahai Pharmaceutical
Langnuo Pharmaceutical
QILU Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Gan & Lee Pharmaceuticals
Kelun Pharmaceutical
YOKO Pharmaceutical
Disainuo Pharmaceutical
Reyoung Pharmaceutical
Segment by Type
Sitagliptin
Vildagliptin
Saxagliptin
Alogliptin
Linagliptin
Others
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of DPP-4 Inhibitor Hypoglycemic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of DPP-4 Inhibitor Hypoglycemic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Overview
1.1 Product Overview and Scope of DPP-4 Inhibitor Hypoglycemic Drugs
1.2 DPP-4 Inhibitor Hypoglycemic Drugs Segment by Type
1.2.1 Global DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Sitagliptin
1.2.3 Vildagliptin
1.2.4 Saxagliptin
1.2.5 Alogliptin
1.2.6 Linagliptin
1.2.7 Others
1.3 DPP-4 Inhibitor Hypoglycemic Drugs Segment by Application
1.3.1 Global DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Size Estimates and Forecasts
1.4.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue 2019-2030
1.4.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales 2019-2030
1.4.3 Global DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Competition by Manufacturers
2.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Average Price by Manufacturers (2019-2024)
2.4 Global DPP-4 Inhibitor Hypoglycemic Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of DPP-4 Inhibitor Hypoglycemic Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of DPP-4 Inhibitor Hypoglycemic Drugs, Product Type & Application
2.7 DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Competitive Situation and Trends
2.7.1 DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest DPP-4 Inhibitor Hypoglycemic Drugs Players 麻豆原创 Share by Revenue
2.7.3 Global DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 DPP-4 Inhibitor Hypoglycemic Drugs Retrospective 麻豆原创 Scenario by Region
3.1 Global DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Region: 2019-2030
3.2.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Region: 2019-2024
3.2.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Region: 2025-2030
3.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Region: 2019-2030
3.3.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Region: 2019-2024
3.3.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Region: 2025-2030
3.4 North America DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Facts & Figures by Country
3.4.1 North America DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2019-2030)
3.4.3 North America DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Facts & Figures by Country
3.5.1 Europe DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2019-2030)
3.5.3 Europe DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Facts & Figures by Country
3.7.1 Latin America DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2019-2030)
3.7.3 Latin America DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2019-2030)
4.1.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2019-2024)
4.1.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2025-2030)
4.1.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Type (2019-2030)
4.2.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Type (2019-2024)
4.2.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Type (2025-2030)
4.2.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2019-2030)
5.1.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2019-2024)
5.1.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2025-2030)
5.1.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Application (2019-2030)
5.2.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Application (2019-2024)
5.2.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue by Application (2025-2030)
5.2.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 MSD Pharma
6.2.1 MSD Pharma Corporation Information
6.2.2 MSD Pharma Description and Business Overview
6.2.3 MSD Pharma DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 MSD Pharma DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.2.5 MSD Pharma Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Novartis DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 AstraZeneca Pharmaceuticals
6.4.1 AstraZeneca Pharmaceuticals Corporation Information
6.4.2 AstraZeneca Pharmaceuticals Description and Business Overview
6.4.3 AstraZeneca Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AstraZeneca Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.4.5 AstraZeneca Pharmaceuticals Recent Developments/Updates
6.5 Takeda Pharmaceutical
6.5.1 Takeda Pharmaceutical Corporation Information
6.5.2 Takeda Pharmaceutical Description and Business Overview
6.5.3 Takeda Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Takeda Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.5.5 Takeda Pharmaceutical Recent Developments/Updates
6.6 Boehringer Ingelheim International
6.6.1 Boehringer Ingelheim International Corporation Information
6.6.2 Boehringer Ingelheim International Description and Business Overview
6.6.3 Boehringer Ingelheim International DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Boehringer Ingelheim International DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.6.5 Boehringer Ingelheim International Recent Developments/Updates
6.7 Huahai Pharmaceutical
6.6.1 Huahai Pharmaceutical Corporation Information
6.6.2 Huahai Pharmaceutical Description and Business Overview
6.6.3 Huahai Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Huahai Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.7.5 Huahai Pharmaceutical Recent Developments/Updates
6.8 Langnuo Pharmaceutical
6.8.1 Langnuo Pharmaceutical Corporation Information
6.8.2 Langnuo Pharmaceutical Description and Business Overview
6.8.3 Langnuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Langnuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.8.5 Langnuo Pharmaceutical Recent Developments/Updates
6.9 QILU Pharmaceutical
6.9.1 QILU Pharmaceutical Corporation Information
6.9.2 QILU Pharmaceutical Description and Business Overview
6.9.3 QILU Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 QILU Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.9.5 QILU Pharmaceutical Recent Developments/Updates
6.10 Chia Tai-Tianqing Pharmaceutical
6.10.1 Chia Tai-Tianqing Pharmaceutical Corporation Information
6.10.2 Chia Tai-Tianqing Pharmaceutical Description and Business Overview
6.10.3 Chia Tai-Tianqing Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Chia Tai-Tianqing Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.10.5 Chia Tai-Tianqing Pharmaceutical Recent Developments/Updates
6.11 Gan & Lee Pharmaceuticals
6.11.1 Gan & Lee Pharmaceuticals Corporation Information
6.11.2 Gan & Lee Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Description and Business Overview
6.11.3 Gan & Lee Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Gan & Lee Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.11.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
6.12 Kelun Pharmaceutical
6.12.1 Kelun Pharmaceutical Corporation Information
6.12.2 Kelun Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Description and Business Overview
6.12.3 Kelun Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Kelun Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.12.5 Kelun Pharmaceutical Recent Developments/Updates
6.13 YOKO Pharmaceutical
6.13.1 YOKO Pharmaceutical Corporation Information
6.13.2 YOKO Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Description and Business Overview
6.13.3 YOKO Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 YOKO Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.13.5 YOKO Pharmaceutical Recent Developments/Updates
6.14 Disainuo Pharmaceutical
6.14.1 Disainuo Pharmaceutical Corporation Information
6.14.2 Disainuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Description and Business Overview
6.14.3 Disainuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Disainuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.14.5 Disainuo Pharmaceutical Recent Developments/Updates
6.15 Reyoung Pharmaceutical
6.15.1 Reyoung Pharmaceutical Corporation Information
6.15.2 Reyoung Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Description and Business Overview
6.15.3 Reyoung Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Reyoung Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
6.15.5 Reyoung Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 DPP-4 Inhibitor Hypoglycemic Drugs Industry Chain Analysis
7.2 DPP-4 Inhibitor Hypoglycemic Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 DPP-4 Inhibitor Hypoglycemic Drugs Production Mode & Process
7.4 DPP-4 Inhibitor Hypoglycemic Drugs Sales and 麻豆原创ing
7.4.1 DPP-4 Inhibitor Hypoglycemic Drugs Sales Channels
7.4.2 DPP-4 Inhibitor Hypoglycemic Drugs Distributors
7.5 DPP-4 Inhibitor Hypoglycemic Drugs Customers
8 DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Dynamics
8.1 DPP-4 Inhibitor Hypoglycemic Drugs Industry Trends
8.2 DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Drivers
8.3 DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Challenges
8.4 DPP-4 Inhibitor Hypoglycemic Drugs 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Merck
MSD Pharma
Novartis
AstraZeneca Pharmaceuticals
Takeda Pharmaceutical
Boehringer Ingelheim International
Huahai Pharmaceutical
Langnuo Pharmaceutical
QILU Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Gan & Lee Pharmaceuticals
Kelun Pharmaceutical
YOKO Pharmaceutical
Disainuo Pharmaceutical
Reyoung Pharmaceutical
听
听
*If Applicable.